The Journal of Immunology, Vol 153, Issue 6 2738-2749, Copyright © 1994 by American Association of Immunologists

ARTICLES

Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts

ML Alegre, LJ Peterson, DR Jeyarajah, M Weiser, JA Bluestone and JR Thistlethwaite
Ben May Institute, Department of Pathology, Pritzker School of Medicine, University of Chicago, IL 60637.

Previous studies have shown that human hemopoietic cells can be adoptively transferred into immunodeficient C.B-17 scid/scid (SCID) mice that lack autologous T and B lymphocytes, to generate chimeric animals. The future development of novel immunomodulatory drugs in transplantation will depend increasingly on experimental animal models to investigate the properties of the agents on human cells before starting clinical trials. However, in previous models of SCID mice engrafted with human PBLs, human T cells have been found either to be in an unresponsive state, unable to respond to mitogenic stimulations in vitro, or to mediate skin graft rejection only when HLA-primed in vivo before their adoptive transfer into SCID mice. In addition, T cells and other leukocyte subsets engraft quite poorly in the lymphoid tissues of the animals. In an attempt to develop a useful model for transplantation research, we have inoculated SCID mice with fresh human splenocytes from cadaveric organ donors (hu-Spl-SCID mice). In this model, various leukocyte subsets engraft effectively in different lymphoid compartments. In addition, human T cells retain their proliferative responses to mitogens and to alloantigens when tested 3 wk after engraftment into SCID mice. Finally, mice engrafted with unprimed human spleen cells acutely reject human foreskin allografts. Treatment of hu-Spl-SCID mice with OKT3, an immunosuppressive mAb directed against the human CD3 complex associated with the TCR, prevents the rejection of most human skin allografts, indicating a major role for human T cells in this phenomenon. Thus, this hu-Spl-SCID model may be useful for the study of immunosuppressive therapies in a preclinical in vivo setting.

This article has been cited by other articles:

				N. A. Turgeon, S. J. Banuelos, L. D. Shultz, B. L. Lyons, N. Iwakoshi, D. L. Greiner, J. P. Mordes, A. A. Rossini, and M. C. Appel Alloimmune Injury and Rejection of Human Skin Grafts on Human Peripheral Blood Lymphocyte-Reconstituted Non-Obese Diabetic Severe Combined Immunodeficient {beta}2-Microglobulin-Null Mice Experimental Biology and Medicine, October 1, 2003; 228(9): 1096 - 1104. [Abstract] [Full Text] [PDF]

				N. Delhem, F. Hadida, G. Gorochov, F. Carpentier, J.-P. de Cavel, J.-F. Andreani, B. Autran, and J.-Y. Cesbron Primary Th1 Cell Immunization Against HIVgp160 in SCID-hu Mice Coengrafted with Peripheral Blood Lymphocytes and Skin J. Immunol., August 15, 1998; 161(4): 2060 - 2069. [Abstract] [Full Text] [PDF]

				A. G. Murray, J. S. Schechner, D. E. Epperson, P. Sultan, J. M. McNiff, C. C. W. Hughes, M. I. Lorber, P. W. Askenase, and J. S. Pober Dermal Microvascular Injury in the Human Peripheral Blood Lymphocyte Reconstituted-Severe Combined Immunodeficient (HuPBL-SCID) Mouse/Skin Allograft Model Is T Cell Mediated and Inhibited by a Combination of Cyclosporine and Rapamycin Am. J. Pathol., August 1, 1998; 153(2): 627 - 638. [Abstract] [Full Text] [PDF]

				P. Brams, M.-L. Nguyen, S. Chamat, I. Royston, and P. R. Morrow Antigen-Specific IgG Responses from Naive Human Splenocytes: In Vitro Priming Followed by Antigen Boost in the SCID Mouse J. Immunol., March 1, 1998; 160(5): 2051 - 2058. [Abstract] [Full Text] [PDF]